Furthermore, INSL5‐overexpressing NPC tumor displayed chemoresistance to conventional chemotherapy, which can be reversed by glycolysis inhibitors 2‐DG (Vander Heiden, 2011) or anti‐INSL5/GPCR142 neutralizing antibodies. Here, INSL5 is linked to nasopharyngeal carcinoma.